New drug cocktail targets Hard-to-Treat lung cancer
NCT ID NCT07463677
First seen Mar 13, 2026 · Last updated Jun 19, 2026 · Updated 15 times
Summary
This Phase 2 trial tests a combination of two drugs, tunlametinib and cetuximab β, in 55 people with advanced non-small cell lung cancer that has a KRAS mutation and has not responded to prior treatments. The goal is to see if the combo can shrink tumors and control the disease. The study is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tunlametinib and Cetuximab β
What this could lead to
If successful, this combination could offer a new treatment option for people with a specific type of advanced lung cancer that has not responded to other therapies.
What could go wrong
This is an early Phase 2 trial with only 55 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink tumors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.